Tbio WDYHV1 Protein N-terminal glutamine amidohydrolase

Protein Summary

Description

Mediates the side-chain deamidation of N-terminal glutamine residues to glutamate, an important step in N-end rule pathway of protein degradation. Conversion of the resulting N-terminal glutamine to glutamate renders the protein susceptible to arginylation, polyubiquitination and degradation as specified by the N-end rule. Does not act on substrates with internal or C-terminal glutamine and does not act on non-glutamine residues in any position. Does not deaminate acetylated N-terminal glutamine. With the exception of proline, all tested second-position residues on substrate peptides do not greatly influence the activity. In contrast, a proline at position 2, virtually abolishes deamidation of N-terminal glutamine.

Uniprot Accession IDs

• Q96HA8
• B4DE68
• Q9NW95

Gene Name

• WDYHV1

Ensembl ID

• ENST00000287387
• ENSP00000287387
• ENSG00000156795
• ENST00000523984
• ENSP00000430427
• ENST00000524254
• ENSP00000497832

Symbol

• C8orf32
• NTAQ1
• C8orf32

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
histone modification site profile	0.89
transcription factor perturbation	0.84
transcription factor binding site profile	0.68
tissue sample	0.51
tissue	0.45

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 7.52   (req: < 5)

Gene RIFs: 1   (req: <= 3)

Antibodies: 60   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 7.52   (req: >= 5)

Gene RIFs: 1   (req: > 3)

Antibodies: 60   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 3

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0